Accordingly, MM cells isolated from the BM of Patients 1, 2 and 3 and cultured under static conditions appeared to be sensitive to Bortezomib treatment (50 nM) as indicated by the percentage of Annexin V+/PI+cells at FACS analysis (71%; 64% and 52%, respectively at 24 hrs, and almost 100% at three days in all cases). The gene discussed is ANXA5; the disease is Miyoshi myopathy.